Barclays set a €110.00 ($127.91) price objective on MorphoSys (ETR:MOR) in a research report sent to investors on Tuesday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
Several other analysts have also issued reports on the stock. Royal Bank of Canada set a €130.00 ($151.16) target price on shares of MorphoSys and gave the company a buy rating in a research report on Thursday, March 19th. JPMorgan Chase & Co. reiterated a buy rating on shares of MorphoSys in a research report on Thursday, March 19th. Deutsche Bank set a €129.00 ($150.00) target price on shares of MorphoSys and gave the company a buy rating in a research report on Tuesday, March 3rd. Berenberg Bank set a €150.00 ($174.42) target price on shares of MorphoSys and gave the company a buy rating in a research report on Monday. Finally, Goldman Sachs Group reiterated a neutral rating on shares of MorphoSys in a research report on Wednesday, January 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. MorphoSys presently has an average rating of Buy and a consensus target price of €122.88 ($142.88).
Shares of ETR MOR opened at €91.65 ($106.57) on Tuesday. The company’s 50-day simple moving average is €99.88 and its 200-day simple moving average is €108.17. MorphoSys has a 52-week low of €79.70 ($92.67) and a 52-week high of €146.30 ($170.12). The firm has a market cap of $3.06 billion and a price-to-earnings ratio of -30.13. The company has a quick ratio of 7.63, a current ratio of 7.80 and a debt-to-equity ratio of 9.78.
MorphoSys Company Profile
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Recommended Story: Trade War
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.